Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
Emergent BioSolutions (NYSE:EBS) received a contract modification worth approximately $64.5 million from ASPR, part of U.S. HHS, under its existing 10-year agreement to supply BAT botulism antitoxin.
BAT treats symptomatic botulism in adults and pediatric patients; effectiveness is based on animal studies. Key warnings include hypersensitivity, infusion reactions, serum sickness, blood sugar test interference, and rare serious adverse reactions.
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
Additional $64.5 million funding under existing 10-year BAT contract with ASPR
Supports continued supply of BAT botulism antitoxin for U.S. biodefense needs
Leverages USMCA-compliant facilities and North American supply chain for government medical countermeasures
Negative
BAT carries risks of hypersensitivity, including anaphylaxis, requiring monitoring during and after infusion
One serious adverse reaction of hemodynamic instability reported in a BAT clinical study patient
Key Figures
Contract modification value:$64.5 millionContract term:10-year contractNeurotoxin serotypes:7 serotypes (A–G)+3 more
6 metrics
Contract modification value$64.5 millionBAT® contract modification with ASPR/HHS
Contract term10-year contractExisting BAT® supply agreement with ASPR
Neurotoxin serotypes7 serotypes (A–G)Botulinum neurotoxin coverage for BAT®
Common adverse reactions (volunteers)≥5%Headache, nausea, pruritus, urticaria in healthy volunteers
Common adverse reactions (patients)≥1%Pyrexia, rash, chills, nausea, edema in clinical study
Serious adverse reaction1 caseHemodynamic instability in clinical study
Market Reality Check
Price:$9.12Vol:Volume 684,238 is below t...
normal vol
$9.12Last Close
VolumeVolume 684,238 is below the 20-day average of 791,725, suggesting no pre-news accumulation.normal
TechnicalShares at 9.02 are trading below the 200-day moving average of 9.75, reflecting a subdued longer-term trend before this contract news.
Peers on Argus
Before this news, EBS was down 1.42% while peers showed mixed, mostly modest mov...
Before this news, EBS was down 1.42% while peers showed mixed, mostly modest moves (e.g., ETON up 4.52%, EOLS down 2.06%). This points to stock-specific dynamics rather than a coordinated sector move.
Multi-year, ~$50M SAB-142 manufacturing deal for type 1 diabetes candidate.
Pattern Detected
Recent fundamental and regulatory positives (approvals, earnings, contracts) have usually seen aligned, positive next-day moves, with only one notable divergence.
Recent Company History
Over the past month, Emergent reported Q1 2026 revenue of $156.1 million with net income of $6.8 million and announced major contracts, including a roughly $50 million manufacturing deal and about $140 million in Canadian government business. It also secured new and expanded approvals for ACAM2000 in Saudi Arabia and Singapore and signaled active investor engagement via conferences in late May and early June. These events collectively highlight a strategy centered on government contracts and specialized vaccines, consistent with today’s BAT® contract update.
Market Pulse Summary
This announcement highlights a $64.5 million contract modification for BAT®, reinforcing Emergent’s ...
Analysis
This announcement highlights a $64.5 million contract modification for BAT®, reinforcing Emergent’s role in U.S. biodefense and its focus on medical countermeasures across botulinum neurotoxin serotypes A–G. In recent months, the company reported profitable Q1 2026 results, secured major government contracts, and gained new international approvals for ACAM2000. Investors monitoring this story may focus on contract durability, product safety profile, and how such awards contribute to revenue stability alongside manufacturing partnerships.
Key Terms
botulism, botulinum neurotoxin, immune globulin, anaphylaxis, +4 more
8 terms
botulismmedical
"indicated for the treatment of symptomatic botulism following documented or suspected exposure"
Botulism is a rare but serious illness caused by a nerve-blocking toxin produced by certain bacteria; it prevents muscles from receiving signals, which can lead to paralysis and breathing failure if untreated. For investors, botulism matters because outbreaks or contamination can trigger product recalls, regulatory actions, liability claims, and sudden shifts in consumer confidence or supply chains, while treatments and prevention efforts can create regulatory and commercial opportunities for medical products and services.
botulinum neurotoxinmedical
"exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults"
A botulinum neurotoxin is a naturally produced bacterial protein that acts like a tiny switch that temporarily turns off nerve signals to muscles or glands. It matters to investors because versions of this toxin are developed into prescription and cosmetic drugs with significant market value, but they also carry strict safety, manufacturing and regulatory risks—so approvals, recalls, or legal issues can strongly affect a company’s revenue and valuation.
immune globulinmedical
"BAT® is a mixture of immune globulin fragments indicated for the treatment"
A laboratory-made preparation of antibodies collected from donated blood that is given to people to prevent or treat infections and immune system problems. Investors should care because immune globulin is a medicinal product with steady clinical demand, complex supply chains and regulation, and measurable pricing and reimbursement dynamics—think of it as a ready-made toolbox for the immune system whose availability and approval can drive a company’s revenue and risk profile.
anaphylaxismedical
"Warnings and Precautions: Hypersensitivity reactions including anaphylaxis."
Anaphylaxis is a sudden, severe allergic reaction in which the body's defense system overreacts to a trigger (like a drug, food, or insect sting), causing widespread symptoms such as difficulty breathing, low blood pressure, and shock; it can be life‑threatening without prompt treatment. Investors care because anaphylaxis risks can affect a drug or product's safety profile, regulatory approval, liability exposure and market acceptance—similar to a sprinkler system going off and damaging the whole house rather than just one room.
serum sicknessmedical
"Delayed allergic reactions (serum sickness). Patient monitoring is recommended."
An immune reaction that can occur days to weeks after exposure to certain medicines, antitoxins, or biological products when the body reacts to foreign proteins, causing fever, rash, joint pain and swollen lymph nodes. Think of the immune system’s alarm system overreacting and causing temporary inflammation. For investors it matters because such reactions affect a drug’s safety profile, can trigger additional testing, label warnings, regulatory delays or liability, and therefore influence commercial prospects and valuation.
pyrexiamedical
"The most common adverse reactions reported in ≥1% of patients... were pyrexia, rash, chills"
Pyrexia is the medical term for a fever—an elevated body temperature that signals the body is fighting infection, inflammation, or reacting to a medication. For investors, pyrexia matters because it is a common safety signal in clinical trials and product use that can delay approvals, trigger additional testing, or affect workforce health and production; think of it as a warning light that prompts further investigation into a drug or operation.
urticariamedical
"healthy volunteers in clinical trials were headache, nausea, pruritus, and urticaria."
A skin condition characterized by itchy, raised red bumps or welts (commonly called hives) that can appear suddenly and come and go; think of it as the skin’s temporary alarm system reacting to something internal or external. Investors care because its prevalence, treatment options, and safety or efficacy data from drugs and devices affect demand, regulatory decisions, clinical trial outcomes, and potential liability or reputational risk for companies in healthcare sectors.
equine plasmamedical
"BAT® is made from equine plasma and may contain infectious agents"
Equine plasma is the liquid portion of a horse’s blood, collected and processed for medical use as a source of antibodies and other proteins. Investors should view it as a raw biological ingredient: like flour for a bakery, its availability, quality and regulatory approval affect the production, cost and reliability of certain veterinary and human biologic treatments. Supply disruptions, animal-health rules or lab testing standards can directly influence companies that rely on it.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS), for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C00075) whereby Emergent will supply BAT®, an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in both adults and pediatric patients.
“Securing this contract modification demonstrates Emergent’s ongoing support of U.S. biodefense and preparedness priorities,” said Paul Williams, head of products business, global government & public affairs at Emergent. “We are proud to leverage our North American supply chain and specialized capabilities to deliver critical medical countermeasures to help protect military and civilian populations.”
Emergent specializes in developing, manufacturing and supplying medical countermeasures for national security and health preparedness through its network of USMCA-compliant facilities. These products support how the U.S. and allied governments respond to emergencies and help protect the public from potential threats.
Indication and Important Safety Information for BAT®
BAT® is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. The effectiveness of BAT® is based solely on efficacy studies conducted in animal models of botulism.
Warnings and Precautions: Hypersensitivity reactions including anaphylaxis. Prepare for monitoring and management of allergic reactions during and after BAT® infusion. Delayed allergic reactions (serum sickness). Patient monitoring is recommended. Infusion reactions. Monitor and slow or interrupt infusion and administer treatment based on the severity of the reaction. Interference with non-glucose specific blood sugar testing systems. Use glucose-specific testing systems. Transmissible Infectious Agents. BAT® is made from equine plasma and may contain infectious agents (e.g., viruses).
Adverse Reactions: The most common adverse reactions observed in ≥5% of healthy volunteers in clinical trials were headache, nausea, pruritus, and urticaria. The most common adverse reactions reported in ≥1% of patients in a clinical study were pyrexia, rash, chills, nausea, and edema. One serious adverse reaction of hemodynamic instability was observed in one patient in the clinical study.
About Emergent BioSolutions At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Safe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the development, availability, and government procurement of BAT® are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.
Investor Contact: Richard S. Lindahl Executive Vice President, CFO lindahlr@ebsi.com
What contract did Emergent BioSolutions (NYSE:EBS) receive for BAT on May 28, 2026?
Emergent BioSolutions received a $64.5 million contract modification from ASPR to supply BAT botulism antitoxin. According to Emergent, this modifies an existing 10-year contract to provide BAT for treating symptomatic botulism in adults and pediatric patients after suspected or confirmed exposure.
How does the new BAT contract modification support the U.S. biodefense strategy for EBS stock investors?
The contract modification strengthens Emergent’s role in supplying BAT for U.S. biodefense needs. According to Emergent, BAT is a critical medical countermeasure used to treat symptomatic botulism after exposure, helping protect military and civilian populations through government preparedness programs.
What is BAT botulism antitoxin heptavalent and how is it used?
BAT is a mixture of immune globulin fragments used to treat symptomatic botulism from serotypes A–G. According to Emergent, it is indicated for adults and pediatric patients following documented or suspected exposure to botulinum neurotoxin and is supplied under long-term U.S. government contracts.
How effective is Emergent BioSolutions’ BAT product for treating botulism?
BAT’s effectiveness is based solely on efficacy studies conducted in animal models of botulism. According to Emergent, these animal studies support its indication for treating symptomatic botulism in adults and pediatric patients exposed to botulinum neurotoxin serotypes A through G under emergency preparedness frameworks.
What are the main safety warnings and adverse reactions for BAT botulism antitoxin?
BAT can cause hypersensitivity reactions, including anaphylaxis, serum sickness, and infusion reactions, requiring close monitoring. According to Emergent, common adverse reactions include headache, nausea, pruritus, urticaria, pyrexia, rash, chills, and edema, with one serious hemodynamic instability case reported in a clinical study.
What patient populations can receive BAT according to Emergent BioSolutions?
BAT is indicated for both adults and pediatric patients with symptomatic botulism from serotypes A–G. According to Emergent, it is used after documented or suspected exposure to botulinum neurotoxins and is part of government stockpiles to support national security and health preparedness.
